Moleculin Biotech Secures Hong Kong Patent for Liposomal Annamycin Ahead of Phase 3 Data

With Phase 3 clinical data for Annamycin expected before the end of the current quarter, Moleculin Biotech has added a Hong Kong patent to its formulation IP estate, extending territorial coverage to a jurisdiction that serves as a regulatory and commercial gateway into broader Asian oncology markets. Patent No. 40073244, titled "Method of Reconstituting Liposomal Annamycin," runs through June 25, 2040, and is jointly held with The University of Texas System.

The grant covers Moleculin's proprietary reconstitution method for its multilamellar lipid-based delivery system, the mechanism the company credits for Annamycin's differentiated pharmacokinetic profile relative to conventional anthracyclines. For formulation and CMC teams tracking liposomal oncology assets, the reconstitution step sits at a technically sensitive intersection of drug product stability, sterility assurance, and clinical reproducibility, making method-specific IP a meaningful layer of exclusivity beyond composition-of-matter claims.

Hong Kong joins an existing portfolio that includes allowed, issued, or granted patents across the United States, Australia, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, and Taiwan. The geographic spread reflects a deliberate pre-commercialization IP strategy ahead of potential regulatory filings, consistent with the kind of lifecycle management planning that QA and regulatory affairs leads would expect to see documented under ICH Q10 pharmaceutical quality system frameworks.

Annamycin, also designated naxtarubicin, is in the pivotal MIRACLE trial (MB-108), an adaptive Phase 3 study evaluating the drug in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia. A separate program targets soft tissue sarcoma lung metastases. The compound is designed to circumvent multidrug resistance mechanisms and avoid the cardiotoxicity associated with currently prescribed anthracyclines, a profile that, if confirmed in Phase 3 data, would carry direct implications for treatment protocols in heavily pre-treated AML populations.

The timing of the Hong Kong grant, immediately preceding the first Phase 3 readout, follows a pattern increasingly common among small-cap oncology biotechs: consolidating formulation and process IP before pivotal data enter the public domain and competitive scrutiny intensifies. Regulatory affairs teams monitoring the AML space should note that Moleculin has indicated the MIRACLE trial pathway was substantially shaped with FDA input following the Phase 1B/2 study (MB-106), though future filings and additional agency feedback remain pending.

The first Phase 3 data release, anticipated within the current quarter, will be the next measurable checkpoint against which the breadth of this IP position is tested.

Source: Moleculin Biotech, Inc. via GlobeNewswire, May 8, 2026.